FidoCure^® Veterinary Team Blog

As we round out National Cancer Research Month, we want to highlight the important work being done by FidoCure researchers in comparative oncology. At FidoCure, we’ve pioneered canine cancer research backed by real-world evidence and published our findings in 4 of the most prestigious peer-reviewed scientific journals. Many of these papers are go-to sources for groundbreaking discoveries and advancements in cancer research. Our studies, led by FidoCure’s Head of Veterinary Research, Dr. Lucas Rodrigues, DVM, MS, PhD,  have shed light on the similarities between canine and human cancers, paving the way for novel treatment approaches that could benefit both humans and dogs alike.  Below, you can find the key points of Fidocure’s Nature, Precision Oncology, Elsevier and Veterinary & Comparative Oncology scientific papers.

One out of four pet dogs will be diagnosed with cancer throughout their lifetime. With nearly 6 million new canine cancer diagnoses each year, there is an urgent need for advanced treatments. Fortunately, FidoCure introduces advanced options into the cancer treatment toolbox for veterinarians and dogs, offering hope for improved outcomes.

Hemangiosarcoma is an aggressive, malignant tumor derived from blood vessel cells that grows rapidly, can cause severe bleeding, and has a high metastasis rate. It most commonly affects the spleen but can also occur in the heart, skin, and liver, with certain breeds like German Shepherds, Golden Retrievers, and Labradors at higher risk. Treatment typically involves surgical removal followed by chemotherapy, though targeted therapies and supplemental approaches like metronomic therapy and mushroom extracts are showing promise. Despite aggressive conventional treatment, prognosis remains guarded, with median survival ranging from 1-7 months depending on tumor location and whether chemotherapy is pursued after surgery.

Precision medicine revolutionizes cancer care by tailoring treatments to each patient's tumor, but major roadblocks remain. These top articles dive into the key challenges holding personalized oncology back and emerging solutions companies like FidoCure are exploring. You'll find insights on innovative clinical trial designs, cutting-edge technologies enabling more precise therapies, and even how studying cancer in pet dogs could accelerate new targeted drug development for both human and veterinary medicine. 

Transitional cell carcinoma (TCC) is the most common tumor affecting canine urinary bladders. It is highly invasive, can obstruct urinary outflow, and has a moderate metastasis rate in areas like lymph nodes and lungs. Several factors increase TCC risk, including older flea products, lawn chemicals, obesity, being female, and certain breeds like Scottish Terriers and Shetland Sheepdogs. Treatment typically involves radiation therapy and chemotherapy rather than surgery due to the tumor's invasive nature and location. Furthermore, TCC can be targeted with precision therapies enabled by FidoCure such as trametinib and lapatinib. 

On World Vet Day, we wanted to express our heartfelt gratitude to all our veterinarians and vet techs who work with our dogs. In recognition, we asked FidoCure pet parents to nominate their vets and tell us why  they've made such an immense impact on the lives of their dogs.

{% module_block module "widget_8b6ae59c-f486-4ccd-9fb8-ecda5d68fb4b" %}{% module_attribute "child_css" is_json="true" %}{}{% end_module_attribute %}{% module_attribute "css" is_json="true" %}{}{% end_module_attribute %}{% module_attribute "definition_id" is_json="true" %}null{% end_module_attribute %}{% module_attribute "field_types" is_json="true" %}{"default_text":"group","slides":"group","slideshow_settings":"group","styles":"group"}{% end_module_attribute %}{% module_attribute "label" is_json="true" %}null{% end_module_attribute %}{% module_attribute "module_id" is_json="true" %}98459521332{% end_module_attribute %}{% module_attribute "path" is_json="true" %}"@hubspot/image_slider_gallery"{% end_module_attribute %}{% module_attribute "schema_version" is_json="true" %}2{% end_module_attribute %}{% module_attribute "slides" is_json="true" %}{% raw %}[{"caption":"

At the heart of veterinary science lies a deep compassion for the well-being of our beloved animal companions. This is where FidoCure can make a profound impact on the quality of life of your pet battling cancer by offering hope with targeted therapy to thousands of dogs through genomic sequencing and AI-driven data analysis of cancer mutations. 

Leading Animal Health Expert Dr. Fabian Kausche Joins FidoCure Advisory Board

Thank you to all the veterinary technicians who have helped us enroll over 4500 dogs on the FidoCure platform. We are so thankful for your partnership in fighting cancer on both ends of the leash! 

Enter below for your chance to win:

Canine cancer is a heartbreaking diagnosis that affects millions of beloved pets worldwide. In fact, it’s one of the biggest unmet needs in veterinary medicine. As advancements in our field continue to evolve, FidoCure emerges as a groundbreaking solution, offering a revolutionary approach to treating canine cancer. By harnessing the power of genomic testing, FidoCure provides targeted therapies that are transforming the landscape of canine cancer care.